BioSpace News Archive

Clinical benefit rate of 73% reported in second line relapsed AML patients. Overall Response OOR 45%, CR/CRi rate of 36%

Adoptive immunotherapy under investigation for children and adults with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrate Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status

ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of CALQUENCE in mantle cell lymphoma

Similar Overall and Complete Response Rates Observed Across Frontline AML Patients Ineligible for Intensive Chemotherapy and in High Unmet Need Patients with TP53-Mutant AML

IMBRUVICA® pooled clinical trial analyses presented at ASH demonstrate sustained efficacy and safety in patients with historically poor outcomes

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration has accepted the Investigational New Drug application for ATG-010 combined with R-GDP for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Oncopeptides AB, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases announces updated efficacy and safety data from the ongoing phase 2 ANCHOR combination study, following an oral presentation at the 62nd American Society of Hematology virtual annual meeting.

MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced updated results from a single-arm, registrational study of flotetuzumab, an investigational, bispecific CD123 × CD3 DART® molecule, in patients with primary induction failure and early relapsed acute myeloid leukemia.

85 Percent of Patients Responded to a Single Infusion of Yescarta, Including 74 Percent of Patients Achieving Complete Response